Table 2 Baseline characteristics of participants, by reporting mode

Completed, n (% of total)

290 (84.3%)

54 (15.7%)

344 (100%)

Completed by: n (%)

   Patient

277 (95.5%)

54 (100%)

331 (96.2%)

   Carer

6 (2.1%)

0 (0%)

6 (1.7%)

   Parent

7 (2.4%)

0 (0%)

7 (2.0%)

Age, mean years (range)

51.4 (13-77)^a

61.5 (35-82)

53.1 (13-82)

Sex, n (%) M/F

103/166 (38.3/61.7)

19/35 (35.2/64.8)

122/201 (37.8/62.2)

Diagnosis, n (%) [mean age, %F]

   Rheumatoid arthritis

152 (79.6%) [53.9, 72%]

39 (20.4)% [64.4, 67%]

191 (100%)[56.0, 71%]

   Psoriasis

31 (88.6%) [48.2, 52%]

4 (11.4%) [61.2, 75%]

35 (100%) [49.8, 62%]

   Ankylosing spondylitis

40 (93.0%)[49.1, 25%]

3 (7.0%) [51.3, 33%]

43 (100%) [49.2, 26%]

   Psoriatic arthritis

37 (84.1%) 50.3, 68%]

7 (15.9%) [51.9, 71%]

44 (100%) [50.5, 68%]

   Other^b

30 (96.8%) [41.7, 63%]

1 (3.2%) [48.0, 0%]

31 (100%) [42.1, 62%]

Previous biologics

   N

275

54

329

   Any

59 (21.5%)

6 (11.1%)

65 (19.8%)

   Adulimumab

43 (15.6%)

5 (9.3%)

48 (14.6%)

   Infliximab

11 (4.0%)

1 (1.9%)

12 (3.6%)

Current medications

   N

277

54

331

   Methotrexate

120 (43.3%)

29 (53.7%)

149 (45.0%)

   Sulfasalazine

46 (16.6%)

7 (13.0%)

53 (16.0%)

   Prednisolone

55 (19.9%)

14 (25.9%)

69 (20.8%)

Quality of life

CGI-S

   N

275

54

329

   N ( %) ≥markedly ill)

184 (66.9%)

30 (55.6%)

214 (65.0%)

EQ-5D

   N

265

54

(0.35)

   EQ5D Index, Mean (SD)

0.41 (0.36)

0.45 (0.29)

0.42

   N

139

20

159

   EQ5D VAS, Mean (SD)

47.6 (23.0)

51.2 (21.8)

48.1 (22.8)

HAQ

   N

151

190

   Mean (SD)

1.68 (0.64)^c

1.97

1.74 (0.65)

DLQI

   N

31

4

35

   Mean (SD)

15.5 (8.1)

11.8 (3.4)

15.0 (7.8)